Relmada Therapeutics Inc (OTCMKTS:RLMD) Director Paul Edward Kelly acquired 100,000 shares of the company’s stock in a transaction on Tuesday, May 14th. The stock was acquired at an average cost of $1.50 per share, for a total transaction of $150,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of Relmada Therapeutics stock traded up $0.02 during trading hours on Wednesday, reaching $1.83. The company’s stock had a trading volume of 13,848 shares, compared to its average volume of 20,422. Relmada Therapeutics Inc has a one year low of $0.80 and a one year high of $2.01.
Separately, ValuEngine raised shares of Relmada Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, May 1st.
Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions.
Featured Story: What is a Stop Order?
Receive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.